Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-17T17:21:33.272Z Has data issue: false hasContentIssue false
  • English
  • Français

Underestimation of Harms in Phase I Trials

Published online by Cambridge University Press:  01 January 2021

Karolina Strzebonska  and
Marcin Waligora
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Independent Articles: Commentary
Information
Journal of Law, Medicine & Ethics , Volume 47 , Issue 2: Human Subject Protection , Summer 2019 , pp. 334 - 335
Copyright
Copyright © American Society of Law, Medicine and Ethics 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Fisher, J.A. et al., “Appraising Harm in Phase I Trials: Healthy Volunteers' Accounts of Adverse Events,” Journal of Law, Medicine & Ethics 47, no. 2 (2019): 323-333.Google Scholar
Chen, S.C., Sinaii, N., Bedarida, G., Gregorio, M.A., Emanuel, E., and Grady, C., “Phase 1 Healthy Volunteer Willingness to Participate and Enrollment Preferences,” Clinical Trials 14, no. 5 (2017): 537-546, doi: 10.1177/1740774517722131.CrossRefGoogle Scholar
Chen, supra note 2.Google Scholar
Fisher, supra note 1.Google Scholar
Fisher, supra note 1.Google Scholar
Różyżska, J. J., “What Makes Clinical Labour Different? The Case of Human Guinea Pigging,” Journal of Medical Ethics 44, no. 9 (2018): 638-642, doi:10.1136/medethics-2017-104267.CrossRefGoogle Scholar
Fisher, supra note 1.Google Scholar
Eaton, A., Iasonos, A., Gounder, M.M., Pamer, E.G., Drilon, A., Vulih, D., Smith, G.L., Ivy, S.P., Spriggs, D.R., and Hyman, D.M., “Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxici-ties,” Clinical Cancer Research 22, no. 3 (2016): 553-559, doi: 10.1158/1078-0432.CCR-15-0339.CrossRefGoogle Scholar
Waligora, M. et al., “Risk and Surrogate Benefit for Pediatric Phase I Trials in Oncology: A Systematic Review with Meta-Analysis,” PLOS Medicine 15, no. 2 (2018): e1002505, doi:10.1371/journal.pmed.1002505.CrossRefGoogle Scholar